

Area Containing GFP Tumor
0 10 20 30 40 50 60 70 80
Pre-Tx
Post-Tx
Pre- Tx
Post- Tx
Ad-I FNα2α1/Syn3
Ad-I FNα2b/Syn3
Syn3 Alone
Ad-βgal/Syn3
Ad-IFNα2α1
IFN-α2α1
*
*

FIG. 1



1,000,000
100,000
10,000
1,000
100
10
[IFN] pg/mg
0
1
2
3
4
5
6
7
8
Days post treatment
Intron A 1 tx
Ad-IFN 1 tx
Ad-IFN 2 tx

FIG. 2A



Ad-IFN α in Urothelium
C Ad-IFNα2α1 7 Days
H&E Ad-IFNα2α1 Tx
Ad-IFNα in Tumor
Ad-IFNα2b 7 Days
H&E Ad-IFNα2b Tx

FIG. 2B

FIG. 3A




FIG. 3B




FIG. 3C





FIG. 3D





IFN
CASPASE 3
KU7
253J B-V

FIG. 4A



% caspase 3 activation
90
80
70
60
50
40
30
20
10
0
B-V-72 hr
KU7-72hr
Control
Ad-βgal
Ad-IFNα

FIG. 4B




FIG. 5A




FIG. 5B




FIG. 5C